Condition
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA)
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Mepolizumab
Research Leaders
5 sponsors active, led by University of South Florida
Related Conditions
Often studied with 6 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Mepolizumab1
- Online Questionnaire1
Active Sponsors
- University of South Florida1
- European EGPA Study Group1
- GSK1
- University of Oxford1
- University of Pennsylvania1
Top Investigators
University of Pennsylvania
University of Oxford
Related Conditions
- Granulomatosis With Polyangiitis Wegeners Gpa1
- Wegener Granulomatosis Wg1
- Ancaassociated Vasculitis Aav1
- Microscopic Polyangiitis Mpa1
- Vasculitis1